Pain Management
Resources
Basic InformationLatest News
More Patients Turning to Medical Marijuana for Arthritis PainCould an Injected Electrode Control Your Pain Without Drugs?If Prescribed Opioids for Pain, Ask Lots of Questions: FDAMore Opioids Doesn't Mean Less Chronic Pain: StudyLegal Pot Products Too Potent for Chronic PainOpioids Won't Help Arthritis Patients Long-Term: StudyFewer Opioids After Eye Surgery Don't Mean More Post-Op PainTougher Rules on Opioids After Surgery Doesn't Mean More Pain for PatientsHealth Tip: Taking Anti-Inflammatory Drugs1 in 5 Heart Pacemaker Patients Prescribed Opioids After SurgeryUsing Opioids After Vasectomy May Trigger Persistent Use: StudyWhat Are the Risks of Pain Relief Alternatives to Opioids?'Alarming' Number of Lupus Patients Use Opioids for Pain: StudyOpioid Prescriptions for Eye Surgery Patients SurgeDocs Prescribe More Opioids at Certain Time of DayU.S. Opioid Prescription Rate Is 7 Times That of SwedenMany Americans Eying CBD, Pot as Pain Relievers Without Knowing RisksCBD Is the Rage, But More Science Needed on Safety, EffectivenessMixing Marijuana With Opioids May Not Be Good for Mental HealthMany Doctors Refusing Care of People Prescribed OpioidsFewer Opioid Painkillers Can Still Control Surgery PainFDA Grants First Approvals for Generic Versions of LyricaMore Than 5 Million U.S. Cancer Survivors Deal With Chronic PainThe Safer Way to Ease Post-Surgical PainOpioids Prescribed in Hospital Often Tied to Long-Term UseDentists Prescribe Antibiotics Far Too Often: StudyMany Patients Don't Need Opioids After Surgery
Questions and AnswersVideosLinksBook Reviews
Related Topics

Depression: Depression & Related Conditions
Medical Disorders
Mental Disorders
Medications

FDA Grants First Approvals for Generic Versions of Lyrica


HealthDay News
Updated: Jul 23rd 2019

new article illustration

TUESDAY, July 23, 2019 (HealthDay News) -- Nine drug companies have received approval for the first generic versions of Lyrica (pregabalin), the U.S. Food and Drug Administration announced.

The generic versions of Lyrica have been approved to manage neuropathic pain from diabetic peripheral neuropathy or spinal cord injury, postherpetic neuralgia, and fibromyalgia. The agency also approved the generic versions as adjunctive therapy for partial onset seizures in patients aged 17 years and older.

The FDA noted that pregabalin must be dispensed with a patient medication guide. Pregabalin carries the risks for angioedema, hypersensitivity reactions, dyspnea, and wheezing. If patients rapidly discontinue using the drug, they could experience increased seizure frequency or other adverse reactions. As with other antiepileptic drugs, pregabalin could increase the risk for suicidal thoughts or behavior. It could also cause peripheral edema, and providers should be cautious when prescribing pregabalin with thiazolidinedione antidiabetic agents. The most commonly reported side effects of pregabalin include dizziness, somnolence, dry mouth, swelling, blurred vision, weight gain, and difficulty concentrating or paying attention.

Approvals for the generic versions of Lyrica were granted to Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy's Laboratories, InvaGen Pharmaceuticals, MSN Laboratories, Rising Pharmaceuticals, Sciegen Pharmaceuticals, and Teva Pharmaceuticals.

More Information




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net